Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK-positive NSCLC: Implications for disease assessment and management

Lung Cancer

Volumn 88, Issue 3, 2015, Pages 355-359

  Ou, Sai Hong Ignatius ^a,b   Klempner, Samuel J ^a,b   Azada, Michele C ^b   Rausei Mills, Veronica ^c   Duma, Christopher ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HOAG MEMORIAL HOSPITAL PRESBYTERIAN   (United States)

Author keywords

Alectinib; Anaplastic lymphoma kinase rearranged non small cell lung cancer; Brain metastasis; Pseudoprogression; Radiation necrosis; Response assessment in neuro oncology (RANO)

Indexed keywords

ALECTINIB; ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; PROTEIN TYROSINE KINASE;

ADULT; ALK GENE; ARTICLE; BRAIN METASTASIS; BRAIN RADIATION; CASE REPORT; DISEASE ASSESSMENT; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG RESPONSE; FEMALE; GENE; GENE REARRANGEMENT; HEADACHE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; MALE; MIDDLE AGED; NON SMALL CELL LUNG CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PSEUDOPROGRESSION; RADIATION NECROSIS; RECOMMENDED DRUG DOSE; STEREOTACTIC RADIOSURGERY; TREATMENT RESPONSE; TUMOR VOLUME; BIOPSY; BRAIN NEOPLASMS; LUNG TUMOR; METABOLISM; NECROSIS; PATHOLOGY; SECONDARY;

ADULT; BIOPSY; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NECROSIS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84929513468     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2015.03.022     Document Type: Article

References (18)

1. Brandsma D., Stalpers L., Taal W., Sminia P., van den Bent M.J. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008, 9:453-461.
2. Brandes A.A., Franceschi E., Tosoni A., Blatt V., Pession A., Tallini G., et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008, 26:2192-2197.
3. Hegi M.E., Diserens A.C., Gorlia T., Hamou M.F., de Tribolet N., Weller M., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997-1003.
4. Gadgeel S.M., Gandhi L., Riely G.J., Chiappori A.A., West H.L., Azada M.C., et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 2014, 10:1119-1128.
5. Kodama T., Hasegawa M., Takanashi K., Sakurai Y., Kondoh O., Sakamoto H. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol 2014, 74:1023-1028.
6. Costa D.B., Kobayashi S., Pandya S.S., Yeo W.L., Shen Z., Tan W., et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 2011, 29:e443-e445.
7. Takeda M., Okamoto I., Nakagawa K. Clinical impact of continued crizotinib administration after isolated central nervous system progression in patients with lung cancer positive for ALK rearrangement. J Thorac Oncol 2013, 8:654-657.
8. Gan G.N., Weickhardt A.J., Scheier B., Doebele R.C., Gaspar L.E., Kavanagh B.D., et al. Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib. Int J Radiat Oncol Biol Phys 2014, 88:892-898.
9. Ou S.H., Jänne P.A., Bartlett C.H., Tang Y., Kim D.W., Otterson G.A., et al. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann Oncol 2014, 25:415-422.
10. Mak K.S., Gainor J.F., Niemierko A., Oh K.S., Willers H., Choi N.C., et al. Significance of targeted therapy and genetic alterations in EGFR ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases. Neuro Oncol 2014, [Epub ahead of print, July 22].
11. Costa D.G., Shaw A.T., Ou S.H., Solomon B.J., Riely G.J., Ahn M.J., et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small cell lung cancer and brain metastases. J Clin Oncol 2015, pii:JCO.2014.59.0539 [Epub ahead of print, January 26].
12. Chamberlain M.C., Glantz M.J., Chalmers L., Van Horn A., Sloan A.E. Early necrosis following concurrent temodar and radiotherapy in patients with glioblastoma. J Neurooncol 2006, 82:82-83.
13. Stuplich M., Hadizadeh D.R., Kuchelmeister K., Scorzin J., Filss C., Langen K.J., et al. Late and prolonged pseudoprogression in glioblastoma after treatment with lomustine and temozolomide. J Clin Oncol 2012, 30:e180-e183.
14. Wen P.Y., Macdonald D.R., Reardon D.A., Cloughesy T.F., Sorensen A.G., Galanis E., et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010, 28:1963-1972.
15. Lin N.U., Lee E.Q., Aoyama H., Barani I.J., Baumert B.G., Brown P.D., et al. Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. Lancet Oncol 2013, 14(10):e396-e406.
16. Arrondeau J., Ammari S., Besse B., Soria J.C. LDK378 compassionate use for treating carcinomatous meningitis in an ALK translocated non-small-cell lung cancer. J Thorac Oncol 2014, 9:e62-e63.
17. Ou S.H., Sommers K.R., Azada M.C., Garon E.B. Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis. Oncologist 2015, 20:224-226.
18. Gainor J.F., Sherman C.A., Willoughby K., Logan J., Kennedy E., Brastianos P.K., et al. Alectinib salvages CNS metastases in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. J Thorac Oncol 2015, 10:232-236.